The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | MGIP as a stable premalignant entity preceding hematologic malignancy
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the concept of monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy. She highlights that MGIP is a clonal condition with the same B-cell receptor sequences as monoclonal gammopathy of undetermined significance (MGUS) and myeloma, and that over 80% of MGIP cases progress to MGUS or smoldering myeloma. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
